UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer

Cancer research (Chicago, Ill.), 2017-12, Vol.77 (24), p.6863-6879

2017

Link zum Volltext

Verfügbarkeit prüfen

Role of Proprotein Convertases in Prostate Cancer Progression

Neoplasia (New York, N.Y.), 2012-11, Vol.14 (11), p.1032-IN6

2012

Link zum Volltext

Verfügbarkeit prüfen

Thrombin activation of protein C requires prior processing by a liver proprotein convertase

The Journal of biological chemistry, 2017-06, Vol.292 (25), p.10564-10573

2017

Link zum Volltext

Verfügbarkeit prüfen

Disruption of Proprotein Convertase 1/3 (PC1/3) Expression in Mice Causes Innate Immune Defects and Uncontrolled Cytokine Secretion

The Journal of biological chemistry, 2012-04, Vol.287 (18), p.14703-14717

2012

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Furin Inhibitors To Protect against the Activation of Influenza Hemagglutinin H5 and Shiga Toxin

Journal of medicinal chemistry, 2014-01, Vol.57 (1), p.29-41

2014

Link zum Volltext

Verfügbarkeit prüfen

Chymase inhibitor-sensitive synthesis of endothelin-1 (1–31) by recombinant mouse mast cell protease 4 and human chymase

Biochemical pharmacology, 2015-03, Vol.94 (2), p.91-100

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens

The Journal of biological chemistry, 2007-07, Vol.282 (29), p.20847-20853

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeted Ablation of the Chromogranin A (Chga) Gene: Normal Neuroendocrine Dense-Core Secretory Granules and Increased Expression of Other Granins

Molecular endocrinology (Baltimore, Md.), 2006-08, Vol.20 (8), p.1935-1947

2006

Link zum Volltext

Verfügbarkeit prüfen

Biosynthesis of Proopiomelanocortin-Derived Peptides in Prohormone Convertase 2 and 7B2 Null Mice

Endocrinology (Philadelphia), 2004-02, Vol.145 (2), p.519-528

2004

Link zum Volltext

Verfügbarkeit prüfen

Enhancing the Drug-Like Profile of a Potent Peptide PACE4 Inhibitor by the Formation of a Host–Guest Inclusion Complex with β‑Cyclodextrin

Molecular pharmaceutics, 2023-09, Vol.20 (9), p.4559-4573

2023

Link zum Volltext

Verfügbarkeit prüfen

An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells

The Journal of biological chemistry, 2016-11, Vol.291 (47), p.24676-24687

2016

Link zum Volltext

Verfügbarkeit prüfen

Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors

Canadian journal of physiology and pharmacology, 2020-07, Vol.98 (7), p.477

2020

Link zum Volltext

Verfügbarkeit prüfen

Strain-specific steroidal control of pituitary function

Journal of endocrinology, 2007-03, Vol.192 (3), p.515-525

2007

Link zum Volltext

Verfügbarkeit prüfen

Increasing C‑Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines

Journal of medicinal chemistry, 2018-09, Vol.61 (18), p.8457-8467

2018

Link zum Volltext

Verfügbarkeit prüfen

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

The Journal of biological chemistry, 2009-10, Vol.284 (42), p.28856-28864

2009

Link zum Volltext

Verfügbarkeit prüfen

Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue

Journal of medicinal chemistry, 2018-12, Vol.61 (24), p.11250-11260

2018

Link zum Volltext

Verfügbarkeit prüfen

PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression

European journal of cell biology, 2017-08, Vol.96 (5), p.469-475

2017

Link zum Volltext

Verfügbarkeit prüfen

Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9

The Journal of biological chemistry, 2014-06, Vol.289 (25), p.17732-17746

2014

Link zum Volltext

Verfügbarkeit prüfen

Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3

ChemMedChem, 2017-08, Vol.12 (15), p.1169-1172

2017

Link zum Volltext

Verfügbarkeit prüfen

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation

Oncotarget, 2015-02, Vol.6 (6), p.3680-3693

2015

Link zum Volltext

Verfügbarkeit prüfen

Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4

Journal of medicinal chemistry, 2017-04, Vol.60 (7), p.2732-2744

2017

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Structure–Activity Relationship Studies of a Potent PACE4 Inhibitor

Journal of medicinal chemistry, 2014-01, Vol.57 (1), p.98-109

2014

Link zum Volltext

Verfügbarkeit prüfen

Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations

European journal of cell biology, 2017-08, Vol.96 (5), p.476-485

2017

Link zum Volltext

Verfügbarkeit prüfen

The Multi-Leu Peptide Inhibitor Discriminates Between PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate Cancer Cells

Journal of medicinal chemistry, 2012-12, Vol.55 (23), p.10501-10511

2012

Link zum Volltext

Verfügbarkeit prüfen

Substrate Cleavage Analysis of Furin and Related Proprotein Convertases: A COMPARATIVE STUDY

The Journal of biological chemistry, 2008-07, Vol.283 (30), p.20897-20906

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Humans
(21)
Animals
(18)
Mice
(16)
Cell Line, Tumor
(13)
Pharmacology & Pharmacy
(11)
Male
(10)
Proprotein Convertases
(10)
Biochemistry & Molecular Biology
(9)
Cell Biology
(9)
Prostate Cancer
(9)
Serine Endopeptidases - Metabolism
(9)
Chemistry, Medicinal
(8)
Proprotein Convertases - Antagonists & Inhibitors
(8)
Proprotein Convertases - Metabolism
(7)
Serine Endopeptidases - Genetics
(7)
Female
(6)
Oncology
(6)
Pace4
(6)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer

Role of Proprotein Convertases in Prostate Cancer Progression

Thrombin activation of protein C requires prior processing by a liver proprotein convertase

Disruption of Proprotein Convertase 1/3 (PC1/3) Expression in Mice Causes Innate Immune Defects and Uncontrolled Cytokine Secretion

Optimization of Furin Inhibitors To Protect against the Activation of Influenza Hemagglutinin H5 and Shiga Toxin

Chymase inhibitor-sensitive synthesis of endothelin-1 (1–31) by recombinant mouse mast cell protease 4 and human chymase

Targeting Host Cell Furin Proprotein Convertases as a Therapeutic Strategy against Bacterial Toxins and Viral Pathogens

Targeted Ablation of the Chromogranin A (Chga) Gene: Normal Neuroendocrine Dense-Core Secretory Granules and Increased Expression of Other Granins

Biosynthesis of Proopiomelanocortin-Derived Peptides in Prohormone Convertase 2 and 7B2 Null Mice

Enhancing the Drug-Like Profile of a Potent Peptide PACE4 Inhibitor by the Formation of a Host–Guest Inclusion Complex with β‑Cyclodextrin

An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells

Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors

Strain-specific steroidal control of pituitary function

Increasing C‑Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue

PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression

Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9

Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation

Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4

Design, Synthesis, and Structure–Activity Relationship Studies of a Potent PACE4 Inhibitor

Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations

The Multi-Leu Peptide Inhibitor Discriminates Between PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate Cancer Cells

Substrate Cleavage Analysis of Furin and Related Proprotein Convertases: A COMPARATIVE STUDY

Aktive Filter

Suchergebnisse filtern